112 related articles for article (PubMed ID: 10802698)
1. Steering anti-cancer drugs away from the TRAIL.
Nagata S
Nat Med; 2000 May; 6(5):502-3. PubMed ID: 10802698
[No Abstract] [Full Text] [Related]
2. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
3. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
4. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
5. TNF-related apoptosis-inducing ligand (TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential.
Fiorucci G; Vannucchi S; Chiantore MV; Percario ZA; Affabris E; Romeo G
Curr Pharm Des; 2005; 11(7):933-44. PubMed ID: 15777244
[TBL] [Abstract][Full Text] [Related]
6. Tumor therapeutics by design: targeting and activation of death receptors.
Wajant H; Gerspach J; Pfizenmaier K
Cytokine Growth Factor Rev; 2005 Feb; 16(1):55-76. PubMed ID: 15733832
[TBL] [Abstract][Full Text] [Related]
7. Involvement of tumor necrosis factor-alpha receptor 1 and tumor necrosis factor-related apoptosis-inducing ligand-(TRAIL) receptor-2/DR-5, but not Fas, in graft injury in live-donor liver transplantation.
Tashiro H; Itamoto T; Ohdan H; Arihiro K; Tateaki Y; Nakahara H; Ochi M; Hino H; Mizunuma K; Hara H; Tokita D; Onoe T; Ishiyama K; Mitsuta H; Sugino K; Asahara T
Transpl Int; 2004 Nov; 17(10):626-33. PubMed ID: 15502938
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Chopin V; Slomianny C; Hondermarck H; Le Bourhis X
Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702
[TBL] [Abstract][Full Text] [Related]
9. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
van Geelen CM; de Vries EG; Le TK; van Weeghel RP; de Jong S
Br J Cancer; 2003 Jul; 89(2):363-73. PubMed ID: 12865931
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
11. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
12. Hot on the TRAIL of acute promyelocytic leukemia.
Zelent A
Nat Med; 2001 Jun; 7(6):662-4. PubMed ID: 11385499
[No Abstract] [Full Text] [Related]
13. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
Kajiwara K; Saito A; Ogata S; Tanihara M
Biochim Biophys Acta; 2004 Jun; 1699(1-2):131-7. PubMed ID: 15158720
[TBL] [Abstract][Full Text] [Related]
14. The TRAIL DISCussion: It is FADD and caspase-8!
Peter ME
Cell Death Differ; 2000 Sep; 7(9):759-60. PubMed ID: 11042670
[No Abstract] [Full Text] [Related]
15. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.
Lawrence D; Shahrokh Z; Marsters S; Achilles K; Shih D; Mounho B; Hillan K; Totpal K; DeForge L; Schow P; Hooley J; Sherwood S; Pai R; Leung S; Khan L; Gliniak B; Bussiere J; Smith CA; Strom SS; Kelley S; Fox JA; Thomas D; Ashkenazi A
Nat Med; 2001 Apr; 7(4):383-5. PubMed ID: 11283636
[No Abstract] [Full Text] [Related]
16. Protein-based therapeutic approaches targeting death receptors.
French LE; Tschopp J
Cell Death Differ; 2003 Jan; 10(1):117-23. PubMed ID: 12655300
[TBL] [Abstract][Full Text] [Related]
17. Avoiding premature apoptosis of normal epidermal cells.
Qin J; Chaturvedi V; Bonish B; Nickoloff BJ
Nat Med; 2001 Apr; 7(4):385-6. PubMed ID: 11283637
[No Abstract] [Full Text] [Related]
18. [TNF-related apoptosis inducing ligand and its research progress on cancer treatment].
Wei XC; Lin XL; Wang XJ
Sheng Li Ke Xue Jin Zhan; 2001 Jan; 32(1):18-22. PubMed ID: 12545771
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand.
Hasegawa H; Yamada Y; Harasawa H; Tsuji T; Murata K; Sugahara K; Tsuruda K; Ikeda S; Imaizumi Y; Tomonaga M; Masuda M; Takasu N; Kamihira S
Br J Haematol; 2005 Jan; 128(2):253-65. PubMed ID: 15638862
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules.
Choi YJ; Baranowska-Daca E; Nguyen V; Koji T; Ballantyne CM; Sheikh-Hamad D; Suki WN; Truong LD
Kidney Int; 2000 Oct; 58(4):1481-91. PubMed ID: 11012883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
